Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Inovio Pharmaceuticals, Inc. (INO)

1.68   0.02 (1.2%) 01-27 16:00
Open: 1.66 Pre. Close: 1.66
High: 1.71 Low: 1.64
Volume: 2,336,500 Market Cap: 419(M)

Technical analysis

as of: 2023-01-27 4:45:31 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.05     One year: 2.32
Support: Support1: 1.38    Support2: 1.15
Resistance: Resistance1: 1.76    Resistance2: 1.99
Pivot: 1.72
Moving Average: MA(5): 1.69     MA(20): 1.68
MA(100): 1.86     MA(250): 2.32
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 40.1     %D(3): 44.3
RSI: RSI(14): 47.5
52-week: High: 4.28  Low: 1.37
Average Vol(K): 3-Month: 5,500 (K)  10-Days: 4,265 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ INO ] has closed above bottom band by 38.5%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.71 - 1.72 1.72 - 1.73
Low: 1.62 - 1.63 1.63 - 1.64
Close: 1.66 - 1.68 1.68 - 1.7

Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Headline News

Sat, 28 Jan 2023
10 Naruto Characters With Totally Different Abilities In The Games - CBR - Comic Book Resources

Sat, 28 Jan 2023
Experts, students shed light on tech user privacy concerns and ... - The Aggie

Wed, 25 Jan 2023
Something New: PTAB Tackles Section 101 Patent Eligibility - Lexology

Mon, 23 Jan 2023
Italy's Ino Panino bringing its famed sandwiches to Maybe Sammy ... - Good Food

Mon, 23 Jan 2023
Competition - win a night at the opera with the INO - RTE.ie

Sun, 22 Jan 2023
doublet FW23 Runway Show at Paris Fashion Week - HYPEBEAST

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -98 (M)
Shares Float 0 (M)
% Held by Insiders 2.4949e+008 (%)
% Held by Institutions 2.4559e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.4747e+008
EPS Est Next Qtl -0.26
EPS Est This Year -0.95
EPS Est Next Year -1.21
Book Value (p.s.) -1.55
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 889.1
Return on Equity (ttm) -42.8
Qtrly Rev. Growth 1.098e+007
Gross Profit (p.s.) 201.61
Sales Per Share -94.62
EBITDA (p.s.) -2.66097e+008
Qtrly Earnings Growth -3.1291e+008
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value -1.09
Price to Sales -0.02
Price to Cash Flow 0

Stock Dividends

Dividend 4.499e+007
Forward Dividend 4.615e+007
Dividend Yield 2677980000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.